Survival in adolescents and young adults with B-cell non-Hodgkin's lymphoma in a referral hospital in Peru

Abstract

Objective: for adolescents and young adults with B-cell non-Hodgkin lymphoma in Peru. Materials and methods: This retrospective study included patients aged 10-39 years with B-cell non-Hodgkin lymphoma (2010-2016). Characteristics were analyzed using Fisher’s exact test, and survival differences were compared. Results: Thirty-one adolescents and young adult patients (6 with pediatric regimens, and 25 with adult regimens) were included. The 3-year overall survival rate was 100% for the pediatric group and 64% for the adult group (p=0.13). The only patient in the pediatric regimen who relapsed, achieved a second complete remission with Rituximab plus ifosfamide, carboplatin, etoposide and autologous stem cell transplantation, while all patients of the adult regimen group died of progressive disease. Conclusions: our findings suggest that adolescents and young adults with the diagnosis of B-cell Non-Hodgkin’s lymphoma have better survival rates in comparison to those who are treated with adult regimens. Multicenter studies with a larger number of patients are required to confirm these results.